FDA clears Roche/Genentech to market Avastin in ovarian cancer
This article was originally published in Scrip
Executive Summary
Roche and its US subsidiary Genentech were given the go-ahead by the FDA on 14 November to market Avastin (bevacizumab) plus chemotherapy to treat women with platinum-resistant, recurrent ovarian cancer.
You may also be interested in...
FDA Finally Approves Avastin In First-Line Ovarian Cancer
Genentech says it worked closely with the agency to bring the drug to women with earlier-stage disease.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.